Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 3, Pages 725
Publisher
MDPI AG
Online
2020-03-09
DOI
10.3390/jcm9030725
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
- (2019) MASAHIRO KATSURADA et al. ANTICANCER RESEARCH
- 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
- (2019) Mario Jreige et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
- (2019) Yang Wang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer
- (2019) Norimitsu Kasahara et al. LUNG CANCER
- Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors
- (2019) Yoshihiko Sakata et al. Thoracic Cancer
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma
- (2018) Kyoichi Kaira et al. EUROPEAN JOURNAL OF CANCER
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
- (2017) Abhishek D. Garg et al. IMMUNOLOGICAL REVIEWS
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography
- (2017) Kazuki Takada et al. Cancer Medicine
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
- (2016) Laurent Dercle et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis
- (2014) Hyung-Jun Im et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review
- (2014) Charalampos Gkogkou et al. SpringerPlus
- Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors
- (2010) Kyoichi Kaira et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More